JP2016533366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533366A5 JP2016533366A5 JP2016523925A JP2016523925A JP2016533366A5 JP 2016533366 A5 JP2016533366 A5 JP 2016533366A5 JP 2016523925 A JP2016523925 A JP 2016523925A JP 2016523925 A JP2016523925 A JP 2016523925A JP 2016533366 A5 JP2016533366 A5 JP 2016533366A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000005778 DNA damage Effects 0.000 claims description 2
- 231100000277 DNA damage Toxicity 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001235 sensitizing effect Effects 0.000 claims description 2
- 238000011285 therapeutic regimen Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 9
- 238000011269 treatment regimen Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/056,560 | 2013-10-17 | ||
| US14/056,560 US9376448B2 (en) | 2012-04-24 | 2013-10-17 | DNA-PK inhibitors |
| PCT/US2014/061033 WO2015058031A1 (en) | 2013-10-17 | 2014-10-17 | Dna-pk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533366A JP2016533366A (ja) | 2016-10-27 |
| JP2016533366A5 true JP2016533366A5 (OSRAM) | 2017-11-24 |
| JP6374959B2 JP6374959B2 (ja) | 2018-08-15 |
Family
ID=51932571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523925A Active JP6374959B2 (ja) | 2013-10-17 | 2014-10-17 | Ｄｎａ−ｐｋ阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3057959B1 (OSRAM) |
| JP (1) | JP6374959B2 (OSRAM) |
| CN (1) | CN105636958B (OSRAM) |
| AU (1) | AU2014337208B2 (OSRAM) |
| BR (1) | BR112016008423B1 (OSRAM) |
| CA (1) | CA2927392C (OSRAM) |
| DK (1) | DK3057959T3 (OSRAM) |
| ES (1) | ES2671354T3 (OSRAM) |
| HR (1) | HRP20180804T1 (OSRAM) |
| HU (1) | HUE037516T2 (OSRAM) |
| LT (1) | LT3057959T (OSRAM) |
| PL (1) | PL3057959T3 (OSRAM) |
| PT (1) | PT3057959T (OSRAM) |
| RS (1) | RS57306B1 (OSRAM) |
| SI (1) | SI3057959T1 (OSRAM) |
| TR (1) | TR201807411T4 (OSRAM) |
| WO (1) | WO2015058031A1 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2861566T1 (sl) | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| DK2900669T3 (da) | 2012-09-25 | 2019-11-04 | Hoffmann La Roche | Hexahydropyrrolo[3,4-C]pyrrolderivater og relaterede forbindelser som autotaxin (ATX)-inhibitorer og som inhibitorer af lysophosphatidsyre (LPA)-produktion til behandling af f.eks. nyresygdomme |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| JP6496730B2 (ja) | 2013-11-26 | 2019-04-03 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規なオクタヒドロ−シクロブタ［１，２−ｃ；３，４−ｃ’］ジピロール−２−イル |
| CN106103446B (zh) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
| AU2015238541B2 (en) | 2014-03-26 | 2019-09-19 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| KR20180043837A (ko) | 2015-09-04 | 2018-04-30 | 에프. 호프만-라 로슈 아게 | 페녹시메틸 유도체 |
| MX2018001890A (es) | 2015-09-24 | 2018-06-20 | Hoffmann La Roche | Compuestos biciclicos como inhibidores de autotaxina (atx). |
| RU2018114289A (ru) | 2015-09-24 | 2019-10-24 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов аутотаксина (atx) |
| EP3353181B1 (en) | 2015-09-24 | 2021-08-11 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| EP3353178B1 (en) | 2015-09-24 | 2021-07-14 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| AU2017335648B2 (en) * | 2016-09-27 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| CR20190423A (es) | 2017-03-16 | 2019-11-01 | Hoffmann La Roche | Nuevos compuestos biciclícos como inhibidores dobles de atx/ca |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| JP7253500B2 (ja) * | 2017-05-18 | 2023-04-06 | イドーシア ファーマシューティカルズ リミテッド | ピリミジン誘導体 |
| HUE056382T2 (hu) * | 2017-05-18 | 2022-02-28 | Idorsia Pharmaceuticals Ltd | Pirimidin-származékok mint PGE2 receptor modulátorok |
| AU2018269666B2 (en) * | 2017-05-18 | 2022-02-03 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as PGE2 receptor modulators |
| AR111806A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| US11788064B2 (en) | 2018-01-05 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| IL276081B2 (en) | 2018-01-17 | 2023-10-01 | Vertex Pharma | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
| EA202091709A1 (ru) | 2018-01-17 | 2020-11-10 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы днк-пк |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CA3124353A1 (en) * | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN112300126A (zh) * | 2019-07-31 | 2021-02-02 | 山东轩竹医药科技有限公司 | 杂环类dna-pk抑制剂 |
| CN112574211B (zh) * | 2019-09-29 | 2022-06-14 | 山东轩竹医药科技有限公司 | 杂环类激酶抑制剂 |
| CN112574179B (zh) * | 2019-09-29 | 2022-05-10 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
| JP7428806B2 (ja) * | 2019-12-31 | 2024-02-06 | 成都百裕制薬股▲ふん▼有限公司 | プリン誘導体および医薬におけるその使用 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1351946A2 (en) * | 2000-09-01 | 2003-10-15 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| WO2005026129A1 (en) * | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| US20090221581A1 (en) * | 2005-05-25 | 2009-09-03 | Philipp Wabnitz | Methods of treating pain |
| AU2007305016B2 (en) * | 2006-10-02 | 2011-11-03 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| WO2011110612A1 (en) * | 2010-03-10 | 2011-09-15 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| HUE054031T2 (hu) * | 2012-04-24 | 2021-08-30 | Vertex Pharma | DNS-PK inhibitorok |
-
2014
- 2014-10-17 PL PL14800181T patent/PL3057959T3/pl unknown
- 2014-10-17 LT LTEP14800181.1T patent/LT3057959T/lt unknown
- 2014-10-17 DK DK14800181.1T patent/DK3057959T3/en active
- 2014-10-17 CN CN201480057118.6A patent/CN105636958B/zh active Active
- 2014-10-17 PT PT148001811T patent/PT3057959T/pt unknown
- 2014-10-17 BR BR112016008423-3A patent/BR112016008423B1/pt active IP Right Grant
- 2014-10-17 CA CA2927392A patent/CA2927392C/en active Active
- 2014-10-17 JP JP2016523925A patent/JP6374959B2/ja active Active
- 2014-10-17 TR TR2018/07411T patent/TR201807411T4/tr unknown
- 2014-10-17 AU AU2014337208A patent/AU2014337208B2/en active Active
- 2014-10-17 HR HRP20180804TT patent/HRP20180804T1/hr unknown
- 2014-10-17 ES ES14800181.1T patent/ES2671354T3/es active Active
- 2014-10-17 WO PCT/US2014/061033 patent/WO2015058031A1/en not_active Ceased
- 2014-10-17 EP EP14800181.1A patent/EP3057959B1/en active Active
- 2014-10-17 RS RS20180605A patent/RS57306B1/sr unknown
- 2014-10-17 SI SI201430733T patent/SI3057959T1/en unknown
- 2014-10-17 HU HUE14800181A patent/HUE037516T2/hu unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533366A5 (OSRAM) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| JP2017516775A5 (OSRAM) | ||
| JP2016501221A5 (OSRAM) | ||
| CY1120941T1 (el) | Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων | |
| PH12018501812A1 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| RU2015125307A (ru) | Комбинированная терапия | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| WO2015195848A8 (en) | Ezh2 inhibitors for treating lymphoma | |
| EA201791284A1 (ru) | Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака | |
| WO2015154064A3 (en) | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | |
| SG10201805033XA (en) | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| JP2015508103A5 (OSRAM) | ||
| EA201591781A1 (ru) | Химические соединения | |
| MX2017015936A (es) | Nueva composicion farmaceutica que comprende agentes tensioactivos no ionicos. | |
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| JP2016525097A5 (OSRAM) | ||
| JP2015502926A5 (OSRAM) | ||
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания |